Board Meeting Details

The Board of Directors meeting was held on August 14, 2026, commencing at 3:45 PM and concluding at 5:00 PM.

Financial Results Approval

The Board approved the Un-Audited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026.

Documents Submitted

  • Annexure-A: Statement of Un-Audited Financial Results (Standalone & Consolidated) for quarter ended June 30, 2026
  • Annexure-B: Unaudited Segment-wise Revenue, Results, Assets and Liabilities (Standalone and Consolidated) for quarter ended June 30, 2026
  • Annexure-C: Limited Review Report from M/s Rahul Chaudhary & Associates, Chartered Accountants on the Un-Audited Financial Results

Additional Board Resolutions

  • Approved draft Annual Report for the financial year 2025-26
  • Scheduled the 48th Annual General Meeting (AGM) on Monday, September 28, 2026 at 1:00 PM at Hotel Saffron Leaf, GMS Road Dehradun, Uttarakhand-248146

Shareholder Voting Arrangements

Pursuant to rule 20(4)(vii) of the Companies (Management and Administration) Rules, 2014:

  • Cut-off date for determining eligible shareholders: Monday, September 21, 2026
  • Electronic voting period: Friday, September 25, 2026 to Sunday, September 27, 2026

Dividend Declaration and Register Closure

The Board decided to close the Register of Members and Transfer books to enable payment of Final Dividend @10% or Rs. 0.50 per Equity Share for FY 2025-26 (subject to member approval in AGM).

  • Register closure period: Tuesday, September 22, 2026 to Monday, September 28, 2026 (both days inclusive)

Standalone Financial Results (All figures in Rs. Lakhs except EPS)

Q1 FY27 (June 30, 2026) Performance:

  • Net Sales/Income from operations: ₹4,844.16
  • Other Income: ₹10.36
  • Total Revenue: ₹4,854.52
  • Total Expenses: ₹4,545.84
  • Profit before Tax: ₹308.68
  • Total Tax Expenses: ₹43.16
  • Net Profit for the period: ₹265.52
  • Paid-up equity share capital: ₹787.52 (face value ₹5 per share)
  • Basic EPS: ₹1.69
  • Diluted EPS: ₹1.69

Comparative Performance:

| Period | Net Sales | Total Revenue | Net Profit | EPS |

| Q1 FY27 (Jun 2026) | 4,844.16 | 4,854.52 | 265.52 | 1.69 |

| Q4 FY26 (Mar 2026) | 4,216.91 | 4,235.03 | 272.62 | 1.73 |

| Q1 FY26 (Jun 2025) | 4,626.45 | 4,639.13 | 122.08 | 0.78 |

| Full Year FY26 | 17,023.35 | 17,119.80 | 817.25 | 5.19 |

Consolidated Financial Results (All figures in Rs. Lakhs except EPS)

Q1 FY27 (June 30, 2026) Performance:

  • Net Sales/Income from operations: ₹9,633.85
  • Other Income: ₹96.52
  • Total Revenue: ₹9,730.37
  • Total Expenses: ₹9,164.52
  • Profit before Tax: ₹565.85
  • Total Tax Expenses: ₹115.72
  • Net Profit for the period: ₹450.13
  • Attributable to Controlling Interest: ₹340.23
  • Attributable to Non-Controlling Interest: ₹109.89
  • Paid-up equity share capital: ₹787.52
  • Basic EPS: ₹2.16
  • Diluted EPS: ₹2.16

Comparative Performance:

| Period | Net Sales | Total Revenue | Net Profit | EPS |

| Q1 FY27 (Jun 2026) | 9,633.85 | 9,730.37 | 450.13 | 2.16 |

| Q4 FY26 (Mar 2026) | 10,281.57 | 10,473.21 | 717.32 | 2.87 |

| Q1 FY26 (Jun 2025) | 8,930.93 | 8,990.64 | 282.13 | 1.02 |

| Full Year FY26 | 36,800.32 | 37,208.09 | 1,796.88 | 7.71 |

Segment-wise Performance Analysis

Standalone Segment Revenue (Q1 FY27):

  • Agrochemicals: ₹4,382.58
  • Active Pharma Ingredient (API): ₹217.91
  • Unallocated other operating revenue: ₹243.67
  • Total: ₹4,844.16

Consolidated Segment Revenue (Q1 FY27):

  • Agrochemicals: ₹4,382.58
  • Active Pharma Ingredient (API): ₹217.91
  • Pharma Formulation: ₹4,789.69
  • Unallocated other operating revenue: ₹243.67
  • Total: ₹9,633.86

Segment Results (Q1 FY27 Standalone):

  • Agrochemicals: ₹631.34 profit
  • Active Pharma Ingredient (API): ₹(197.56) loss
  • Total Segment Results: ₹433.78

Segment Results (Q1 FY27 Consolidated):

  • Agrochemicals: ₹631.34 profit
  • Active Pharma Ingredient (API): ₹(197.56) loss
  • Pharma Formulation: ₹340.05 profit
  • Total Segment Results: ₹773.84

Assets and Liabilities Position

Standalone (as of June 30, 2026):

  • Total Segment Assets: ₹43,829.43
  • Total Segment Liabilities: ₹7,288.71

Consolidated (as of June 30, 2026):

  • Total Segment Assets: ₹79,882.58
  • Total Segment Liabilities: ₹11,685.07

Auditor Review

M/s Rahul Chaudhary & Associates, Chartered Accountants provided limited review reports for both standalone and consolidated financial results. Their review concluded that nothing came to their attention suggesting material misstatement in the financial results prepared in accordance with Ind AS 34.

Notes to Financial Results

1. The un-audited financial results were reviewed by the Audit Committee and approved by the Board on August 14, 2026

2. The company operates in three business segments: Agro Chemical, Pharma API & Pharma Formulations

3. Consolidated results include results of associate company Medicamen Biotech Limited

4. The Group's share of net profit after tax from associate (Medicamen Biotech) for Q1 FY27: ₹74.68 Lakhs

5. Earning Per Share calculated as per Ind AS-33